HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Chemotherapy-resistant intravascular lymphoma accompanied by ADAMTS13 inhibitor successfully treated with rituximab.

AuthorsMasatoshi Kanno, Shinobu Nakamura, Makoto Kawahara, Satoshi Ueno, Hirokazu Nakamine, Masanori Matsumoto, Yoshihiro Fujimura
JournalInternational journal of hematology (Int J Hematol) Vol. 88 Issue 3 Pg. 345-347 (Oct 2008) ISSN: 1865-3774 [Electronic] Japan
PMID18712462 (Publication Type: Case Reports, Letter)
Chemical References
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Murine-Derived
  • Antineoplastic Agents
  • Autoantibodies
  • Enzyme Inhibitors
  • Rituximab
  • ADAM Proteins
  • ADAMTS13 Protein
  • ADAMTS13 protein, human
Topics
  • ADAM Proteins (antagonists & inhibitors)
  • ADAMTS13 Protein
  • Antibodies, Monoclonal (administration & dosage)
  • Antibodies, Monoclonal, Murine-Derived
  • Antineoplastic Agents (administration & dosage)
  • Autoantibodies (blood)
  • Drug Resistance, Neoplasm (drug effects)
  • Enzyme Inhibitors (blood)
  • Humans
  • Lymphoma, Large B-Cell, Diffuse (blood, diagnosis, drug therapy, enzymology)
  • Male
  • Middle Aged
  • Remission Induction
  • Rituximab

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: